US20060051409A1 - Bezonatate liquid hard capsule dosage form - Google Patents
Bezonatate liquid hard capsule dosage form Download PDFInfo
- Publication number
- US20060051409A1 US20060051409A1 US10/936,378 US93637804A US2006051409A1 US 20060051409 A1 US20060051409 A1 US 20060051409A1 US 93637804 A US93637804 A US 93637804A US 2006051409 A1 US2006051409 A1 US 2006051409A1
- Authority
- US
- United States
- Prior art keywords
- hard capsule
- benzonatate
- bottom half
- pharmaceutical dosage
- bezonatate
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 239000007902 hard capsule Substances 0.000 title claims abstract description 25
- 239000007788 liquid Substances 0.000 title claims abstract description 13
- 239000002552 dosage form Substances 0.000 title description 2
- MAFMQEKGGFWBAB-UHFFFAOYSA-N benzonatate Chemical compound CCCCNC1=CC=C(C(=O)OCCOCCOCCOCCOCCOCCOCCOCCOCCOC)C=C1 MAFMQEKGGFWBAB-UHFFFAOYSA-N 0.000 claims abstract description 21
- 229960003789 benzonatate Drugs 0.000 claims abstract description 20
- 108010010803 Gelatin Proteins 0.000 claims description 4
- 239000008273 gelatin Substances 0.000 claims description 4
- 229920000159 gelatin Polymers 0.000 claims description 4
- 235000019322 gelatine Nutrition 0.000 claims description 4
- 235000011852 gelatine desserts Nutrition 0.000 claims description 4
- 238000007789 sealing Methods 0.000 claims description 3
- 239000002202 Polyethylene glycol Substances 0.000 claims description 2
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims description 2
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims description 2
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims description 2
- 229960003943 hypromellose Drugs 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 229920001223 polyethylene glycol Polymers 0.000 claims description 2
- 239000002775 capsule Substances 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 239000007897 gelcap Substances 0.000 description 5
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
- 238000002690 local anesthesia Methods 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 230000000954 anitussive effect Effects 0.000 description 1
- 229940124584 antitussives Drugs 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- ZZVUWRFHKOJYTH-UHFFFAOYSA-N diphenhydramine Chemical compound C=1C=CC=CC=1C(OCCN(C)C)C1=CC=CC=C1 ZZVUWRFHKOJYTH-UHFFFAOYSA-N 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4816—Wall or shell material
Definitions
- the present invention relates to pharmaceutical dosages and, more specifically, to a pharmaceutical dosage that includes benzonatate in a hard capsule.
- Benzonatate a known composition used as an antitussive, is manufactured in liquid form. Typically, dosages of benzonatate are placed in a soft gel cap. Some patients, especially children, have a tendency to bite into soft gel caps, expecting them to taste like candy. When bitten hard enough, the liquid in the gel cap is released into the patient's mouth. Benzonatate causes local anesthesia in the mouth and throat. This local anesthesia can lead to choking in certain patients. Therefore, there is a need for benzonatate in a form with a reduced likelihood of being released in the patient's mouth.
- gel caps are relatively expensive to produce, requiring solvents to provide the proper finish.
- Typical solvents used include methylene chloride, which is an undesirable material in the finished gel cap and may have undesirable environmental consequences.
- the present invention which, in one aspect, is a pharmaceutical dosage that includes benzonatate, in liquid form, disposed in a hard capsule.
- the invention is a pharmaceutical dosage that includes a hard capsule, benzonatate and a sealer ring.
- the hard capsule has a bottom half and a top half that covers the bottom half.
- the benzonatate is in liquid form and is disposed in the bottom half of the hard capsule.
- the sealer ring seals the top half to the bottom half.
- the invention is a method of making a pharmaceutical dosage, in which liquid benzonatate is placed in a hard capsule.
- the hard capsule is sealed with the liquid benzonatate therein.
- FIG. 1 is a side elevational view of one illustrative embodiment of the invention.
- FIG. 2 is a side elevational view of a second illustrative embodiment of the invention.
- a pharmaceutical dosage 100 that discourages biting includes a hard capsule 110 and liquid form benzonatate 102 that is placed in the hard capsule 110 .
- the hard capsule 110 includes a bottom half 114 , into which the benzonatate is disposed and a top half 112 , that covers a portion of the bottom half 114 .
- a sealer ring 116 may be used to seal the top half 112 to the bottom half 114 .
- One type of sealing machine that may be used to apply the sealer ring includes the S-40 HICAPSEAL, available from Shionogi Qualicaps, Inc., 6505 Franz Warner Parkway, Whitsett, N.C. 27377.
- the hard capsule 110 could be made from materials such as: gelatin, gelatin and polyethylene glycol, and hypromellose.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Preparation (AREA)
Abstract
A pharmaceutical dosage includes a hard capsule, benzonatate and a sealer ring. The hard capsule has a bottom half and a top half that covers the bottom half. The benzonatate is in liquid form and is placed in the bottom half of the hard capsule. The sealer ring seals the top half to the bottom half.
Description
- 1. Field of the Invention
- The present invention relates to pharmaceutical dosages and, more specifically, to a pharmaceutical dosage that includes benzonatate in a hard capsule.
- 2. Description of the Prior Art
- Benzonatate, a known composition used as an antitussive, is manufactured in liquid form. Typically, dosages of benzonatate are placed in a soft gel cap. Some patients, especially children, have a tendency to bite into soft gel caps, expecting them to taste like candy. When bitten hard enough, the liquid in the gel cap is released into the patient's mouth. Benzonatate causes local anesthesia in the mouth and throat. This local anesthesia can lead to choking in certain patients. Therefore, there is a need for benzonatate in a form with a reduced likelihood of being released in the patient's mouth.
- Also, gel caps are relatively expensive to produce, requiring solvents to provide the proper finish. Typical solvents used include methylene chloride, which is an undesirable material in the finished gel cap and may have undesirable environmental consequences.
- Therefore, there is a need for a benzonatate dosage form that has a lower likelihood of being bitten into.
- The disadvantages of the prior art are overcome by the present invention which, in one aspect, is a pharmaceutical dosage that includes benzonatate, in liquid form, disposed in a hard capsule.
- In another aspect, the invention is a pharmaceutical dosage that includes a hard capsule, benzonatate and a sealer ring. The hard capsule has a bottom half and a top half that covers the bottom half. The benzonatate is in liquid form and is disposed in the bottom half of the hard capsule. The sealer ring seals the top half to the bottom half.
- In yet another aspect, the invention is a method of making a pharmaceutical dosage, in which liquid benzonatate is placed in a hard capsule. The hard capsule is sealed with the liquid benzonatate therein.
- These and other aspects of the invention will become apparent from the following description of the preferred embodiments taken in conjunction with the following drawings. As would be obvious to one skilled in the art, many variations and modifications of the invention may be effected without departing from the spirit and scope of the novel concepts of the disclosure.
-
FIG. 1 is a side elevational view of one illustrative embodiment of the invention. -
FIG. 2 is a side elevational view of a second illustrative embodiment of the invention. - A preferred embodiment of the invention is now described in detail. Referring to the drawings, like numbers indicate like parts throughout the views. As used in the description herein and throughout the claims, the following terms take the meanings explicitly associated herein, unless the context clearly dictates otherwise: the meaning of “a,” “an,” and “the” includes plural reference, the meaning of “in” includes “in” and “on.”
- As shown in
FIGS. 1 and 2 , apharmaceutical dosage 100 that discourages biting includes ahard capsule 110 andliquid form benzonatate 102 that is placed in thehard capsule 110. Thehard capsule 110 includes abottom half 114, into which the benzonatate is disposed and atop half 112, that covers a portion of thebottom half 114. - A
sealer ring 116 may be used to seal thetop half 112 to thebottom half 114. One type of sealing machine that may be used to apply the sealer ring includes the S-40 HICAPSEAL, available from Shionogi Qualicaps, Inc., 6505 Franz Warner Parkway, Whitsett, N.C. 27377. As is generally known in the pharmaceutical arts, thehard capsule 110 could be made from materials such as: gelatin, gelatin and polyethylene glycol, and hypromellose. - The above described embodiments are given as illustrative examples only. It will be readily appreciated that many deviations may be made from the specific embodiments disclosed in this specification without departing from the invention. Accordingly, the scope of the invention is to be determined by the claims below rather than being limited to the specifically described embodiments above.
Claims (8)
1. A pharmaceutical dosage, comprising:
a. a hard capsule; and
b. benzonatate, in liquid form, disposed in the hard capsule.
2. The pharmaceutical dosage of claim 1 , wherein the hard capsule comprises:
a. a bottom half, into which the benzonatate is disposed;
b. a top half, that covers a portion of the bottom half;
c. a sealer ring that seals the top half to the bottom half.
3. The pharmaceutical dosage of claim 1 , wherein the hard capsule comprises gelatin.
4. The pharmaceutical dosage of claim 1 , wherein the hard capsule comprises gelatin and polyethylene glycol.
5. The pharmaceutical dosage of claim 1 , wherein the hard capsule comprises hypromellose.
6. A pharmaceutical dosage, comprising:
a. a hard capsule, having a bottom half and a top half that covers a portion of the bottom half;
b. benzonatate, in liquid form, disposed in the bottom half of the hard capsule; and
c. a sealer ring that seals the top half to the bottom half.
7. A method of making a pharmaceutical dosage, comprising the steps of:
a. placing liquid benzonatate in a hard capsule; and
b. sealing the hard capsule with the liquid benzonatate therein.
8. The method of claim 7 , wherein the sealing step comprises applying a sealer ring to the capsule.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US10/936,378 US20060051409A1 (en) | 2004-09-08 | 2004-09-08 | Bezonatate liquid hard capsule dosage form |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US10/936,378 US20060051409A1 (en) | 2004-09-08 | 2004-09-08 | Bezonatate liquid hard capsule dosage form |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| US20060051409A1 true US20060051409A1 (en) | 2006-03-09 |
Family
ID=35996530
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| US10/936,378 Abandoned US20060051409A1 (en) | 2004-09-08 | 2004-09-08 | Bezonatate liquid hard capsule dosage form |
Country Status (1)
| Country | Link |
|---|---|
| US (1) | US20060051409A1 (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109394724A (en) * | 2013-12-21 | 2019-03-01 | 石药集团恩必普药业有限公司 | A kind of butylphthalide liquid hard capsule preparation and preparation method thereof |
| WO2019199830A1 (en) * | 2018-04-10 | 2019-10-17 | Stem Arts Projects, Llc | Capsule for lyophilized reagent storage and delivery |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4975426A (en) * | 1987-06-08 | 1990-12-04 | Analgesic Associates | Cough/cold mixtures comprising non-sedating antihistamine drugs |
| US20030104048A1 (en) * | 1999-02-26 | 2003-06-05 | Lipocine, Inc. | Pharmaceutical dosage forms for highly hydrophilic materials |
| US6793934B1 (en) * | 1999-12-08 | 2004-09-21 | Shire Laboratories, Inc. | Solid oral dosage form |
-
2004
- 2004-09-08 US US10/936,378 patent/US20060051409A1/en not_active Abandoned
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4975426A (en) * | 1987-06-08 | 1990-12-04 | Analgesic Associates | Cough/cold mixtures comprising non-sedating antihistamine drugs |
| US20030104048A1 (en) * | 1999-02-26 | 2003-06-05 | Lipocine, Inc. | Pharmaceutical dosage forms for highly hydrophilic materials |
| US6793934B1 (en) * | 1999-12-08 | 2004-09-21 | Shire Laboratories, Inc. | Solid oral dosage form |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109394724A (en) * | 2013-12-21 | 2019-03-01 | 石药集团恩必普药业有限公司 | A kind of butylphthalide liquid hard capsule preparation and preparation method thereof |
| CN109394724B (en) * | 2013-12-21 | 2021-07-30 | 石药集团恩必普药业有限公司 | A kind of butylphthalide liquid hard capsule preparation and preparation method thereof |
| WO2019199830A1 (en) * | 2018-04-10 | 2019-10-17 | Stem Arts Projects, Llc | Capsule for lyophilized reagent storage and delivery |
| EP3607297A4 (en) * | 2018-04-10 | 2020-12-23 | Stem Arts Projects, LLC | Capsule for lyophilized reagent storage and delivery |
| US10927402B2 (en) | 2018-04-10 | 2021-02-23 | Stem Arts Projects, Llc | Capsule for lyophilized reagent storage and delivery |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US5464631A (en) | Encapsulated dosage forms | |
| ES2567068T3 (en) | Enema with reduced irritation for the treatment of inflammatory bowel disease (IBD) | |
| CA2341024A1 (en) | Non-gelatin substitutes for oral delivery capsules, their composition and process of manufacture | |
| TW201028140A (en) | Pharmaceutical dosages delivery system | |
| US20050053648A1 (en) | Medication delivery device | |
| ATE194290T1 (en) | STABILIZED COMPOSITION FOR ORAL ADMINISTRATION OF PEPTIDES | |
| KR20150036553A (en) | Laquinimod Formulations without Alkalizing Agent | |
| CN1956736A (en) | Oral preparations | |
| US20060051409A1 (en) | Bezonatate liquid hard capsule dosage form | |
| HUT57578A (en) | Process for producing tablet-capsule combination | |
| CN106619128A (en) | Sealed storage composition for capsule and sealed storage method thereof | |
| US20060293641A1 (en) | Housing body for deglutition of solid molding for oral ingestion, container for the housing body, and deglutition method | |
| CN113164405A (en) | Hydroxypropyl methylcellulose hollow capsule | |
| US20140224680A1 (en) | Kit-of-parts | |
| US5626872A (en) | Pharmaceutical soft capsules containing lysine clonixinate and a process for their preparation | |
| US20180369154A1 (en) | Acid-resistant capsule | |
| CN206867447U (en) | A kind of Capsules | |
| CN219354686U (en) | Anti-brittleness gelatin hollow capsule | |
| US20180200191A1 (en) | Multi Component Pill and Method(s) of Use | |
| KR850002400A (en) | Methods for Continuous Release of Medicines and Continuously Released Medicine Products | |
| CN208037164U (en) | Portable medicine taking auxiliary reagent box | |
| ATE383097T1 (en) | DOSAGE FORM FOR THE ORAL ADMINISTRATION OF ACTIVE INGREDIENTS, VITAMINS AND/OR NUTRIENTS | |
| US20060222700A1 (en) | Tablet and capsule form of liquid active ingredient | |
| CN205659160U (en) | Good capsule of leakproofness | |
| IL105870A (en) | Pharmaceutical soft capsules containing lysine clonixinate and their preparation |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| AS | Assignment |
Owner name: MIKART, INC., GEORGIA Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:GROENEWOUD, PIETER J.;REEL/FRAME:015737/0889 Effective date: 20041011 |
|
| STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |